{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04886726",
            "orgStudyIdInfo": {
                "id": "14916"
            },
            "organization": {
                "fullName": "Henry Ford Health System",
                "class": "OTHER"
            },
            "briefTitle": "PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis",
            "officialTitle": "Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation",
            "therapeuticArea": [
                "Other"
            ],
            "study": "ptcy-plus-uhcg-egf-for-graft-versus-host-disease-prophylaxis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-05",
            "studyFirstSubmitQcDate": "2021-05-10",
            "studyFirstPostDateStruct": {
                "date": "2021-05-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Shatha Farhan",
                "investigatorTitle": "Clinical Assistant Professor",
                "investigatorAffiliation": "Henry Ford Health System"
            },
            "leadSponsor": {
                "name": "Henry Ford Health System",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival"
        },
        "conditionsModule": {
            "conditions": [
                "Graft Versus Host Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PTCY and uhCG/EGF",
                    "type": "EXPERIMENTAL",
                    "description": "PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant",
                    "interventionNames": [
                        "Drug: uhCG/EGF"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "uhCG/EGF",
                    "description": "PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant",
                    "armGroupLabels": [
                        "PTCY and uhCG/EGF"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "MTD",
                    "description": "The maximum tolerated dose",
                    "timeFrame": "day+30 post SCT"
                },
                {
                    "measure": "Incidence and severity of dose limiting toxicity (DLTs)",
                    "description": "The overall incidence and severity of DLTs for uhCG/EGF",
                    "timeFrame": "day+30 post SCT"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "acute GVHD",
                    "description": "Cumulative incidence of acute GVHD",
                    "timeFrame": "till day +100 post SCT"
                },
                {
                    "measure": "Chronic GVHD",
                    "description": "Cumulative incidence of chronic GVHD",
                    "timeFrame": "one year post SCT"
                },
                {
                    "measure": "Overall survival",
                    "description": "Death from any cause will be considered an event. Surviving patients will be censored at the time of last follow up.",
                    "timeFrame": "one year post SCT"
                },
                {
                    "measure": "Disease free survival",
                    "description": "Survival following allogeneic SCT without relapse or progression. Relapse or progression of disease, or death are considered events",
                    "timeFrame": "one year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with hematologic malignancy who have the indication for Allogeneic SCT and have no MRD or MUD.\n2. Age 18-70 years old\n3. Performance score of at least 80% by Karnofsky\n4. Adequate kidney and liver function as demonstrated by:\n\n   1. Creatinine clearance should be \\>60 ml/min\n   2. Total Bilirubin \\<1.5, ALT/AST/Alk Phos \\< 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.\n5. Negative Beta HCG test in a woman with childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of childbearing potential must be willing to use an effective contraceptive measure while on study.\n6. Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.\n\nExclusion Criteria:\n\n1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause\n2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.\n3. History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.\n4. Uncontrolled infection\n5. Donor specific antibodies\n6. Ejection fraction \\<40% or history of heart failure or cardiovascular disease\n7. history thrombosis or current thrombosis, family history of thrombosis, severe obesity, or thrombophilia.\n8. Previous history hormone responsive cancer\n9. history of seizure\n10. history of migraine or severe headache\n11. history of asthma\n12. history of uterine fibroid",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "shatha farhan",
                    "role": "CONTACT",
                    "phone": "3137133910",
                    "email": "sfarhan1@hfhs.org"
                }
            ],
            "locations": [
                {
                    "facility": "Henry Ford Hospital",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "shatha farhan",
                            "role": "CONTACT",
                            "phone": "313-713-3910",
                            "email": "sfarhan1@hfhs.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006086",
                    "term": "Graft vs Host Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9189",
                    "name": "Graft vs Host Disease",
                    "asFound": "Graft Versus Host Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2832",
                    "name": "Homologous Wasting Disease",
                    "asFound": "Graft Versus Host Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M9168",
                    "name": "Chorionic Gonadotropin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}